Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oseltamivir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oseltamivir SCHEMBL18117995 | 1.00 | MEN1 (0.81) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL8730 | 1.00 | MEN1 (0.81) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL15912673 | 1.00 | MEN1 (0.81) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL29085770 | 1.00 | MEN1 (0.81) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL28613342 | 0.99 | MEN1 (0.80) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL28299940 | 0.96 | MEN1 (0.75) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL4234896 | 0.96 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL125557 | 0.96 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL14775954 | 0.96 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL14283136 | 0.96 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141965-A1 | TREATMENT OF INFECTIOUS DISEASES | DURECT CORPORATION | 2023-05-11 | — | — | US | disclosed |
| EP-4103195-A1 | TREATMENT OF INFECTIOUS DISEASES | Durect Corporation (US) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021163199-A1 | TREATMENT OF INFECTIOUS DISEASES | DURECT CORPORATION (US) | 2021-08-19 | — | — | WO | disclosed |
| CN-110292593-A | Application of the Cortex Magnoliae Officinalis in preparation Tamiflu | 广州呼吸健康研究院 | 2019-10-01 | — | — | CN | disclosed |
| CN-110292593-A | Application of the Cortex Magnoliae Officinalis in preparation Tamiflu | 广州呼吸健康研究院 | 2019-10-01 | — | — | CN | disclosed |
| CN-107410034-A | Screening technique | 生物联盟有限公司 | 2017-12-01 | — | — | CN | disclosed |
| EP-2005945-B1 | OSELTAMIVIR PHOSPHATE GRANULE AND PREPARATION METHOD THEREOF | INST PHARM & TOXICOLOGY AMMS (CN) | 2016-10-12 | — | — | EP | disclosed |
| CN-105832755-A | Application of combination of hyperoside and oseltamivir to drug for prevention and treatment of H7N9 influenza | 吉林大学 | 2016-08-10 | — | — | CN | disclosed |
| CN-104704109-A | Method for screening microorganisms for conferring useful properties on plants | BIODISCOVERY NEW ZEALAND LTD | 2015-06-10 | — | — | CN | disclosed |
| CN-103607884-A | Screening method | BIODISCOVERY NEW ZEALAND LTD | 2014-02-26 | — | — | CN | disclosed |
| CN-102712928-A | Antisense antiviral compounds and methods of treating influenza virus infection | AVI BIOPHARMA INC | 2012-10-03 | — | — | CN | disclosed |
| US-20120173285-A1 | Proactive Clinical Evidence at Point of Care and Genomic Data Integration through Cloud EMR Media | MUTHUKRISHNAN SURESH (QA) | 2012-07-05 | — | — | US | disclosed |
| US-20120164253-A1 | ANTI-INFLUENZA VIRAL COMPOSITION CONTAINING BARK OR STEM EXTRACT OF ALNUS JAPONICA | RNL BIO CO., LTD. (KR) | 2012-06-28 | — | — | US | disclosed |
| WO-2012003030-A9 | METHODS OF IDENTIFYING & USING ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012003030-A2 | METHODS OF IDENTIFYING & USING ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011133719-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | WO | disclosed |
| CN-102215851-A | Anti-influenza virus composition containing extract of bark or stem of alnus japonica | RNL BIO CO LTD | 2011-10-12 | — | — | CN | disclosed |
| US-20100285160-A1 | ANTI-INFLUENZA VIRAL COMPOSITION CONTAINING BARK OR STEM EXTRACT OF ALNUS JAPONICA | RNL BIO CO., LTD. (KR) | 2010-11-11 | — | — | US | disclosed |
| EP-2222318-A2 | ANTI-INFLUENZA VIRAL COMPOSITION CONTAINING BARK OR STEM EXTRACT OF ALNUS JAPONICA | RNL Bio Co., Ltd. (KR) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009075488-A2 | ANTI-INFLUENZA VIRAL COMPOSITION CONTAINING BARK OR STEM EXTRACT OF ALNUS JAPONICA | RNL BIO CO., LTD (KR) | 2009-06-18 | — | — | WO | disclosed |